Assessment of Targets of Antibody Drug Conjugates in SCLC
Antibody-drug conjugate (ADC) therapy has improved treatment for several solid tumors, including small cell lung cancer (SCLC), but challenges persist. This study investigated the expression of ADC targets SEZ6, DLL3, CD276, and TACSTD2 in SCLC cell lines and patient samples.Here you will find the patient fastq files for the patient samples used in the study.